monarcHER: A Phase 2, Randomized, Multicenter, 3-Arm, Open-Label Study to Compare the Efficacy of Abemaciclib Plus Trastuzumab With or Without Fulvestrant to Standard-of-Care Chemotherapy of Physician's Choice Plus Trastuzumab in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2018
At a glance
- Drugs Abemaciclib (Primary) ; Fulvestrant (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms monarcHER
- Sponsors Eli Lilly
- 02 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 18 Sep 2017 Planned End Date changed from 1 Jun 2019 to 1 Feb 2021.
- 18 Sep 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Aug 2018.